Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1544-1550

  Akinkuolie, Akintunde O ^a   Pradhan, Aruna D ^a   Buring, Julie E ^a   Ridker, Paul M ^b   Mora, Samia ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

diabetes mellitus; epidemiology; glycoprotein; inflammation

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLYCAN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; N ACETYLGLUCOSAMINE; PROTEIN GLYCA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; POLYSACCHARIDE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTURBIDIMETRY; MAJOR CLINICAL STUDY; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TURBIDIMETRY; BLOOD; DIABETES MELLITUS, TYPE 2; INFLAMMATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED;

ACUTE-PHASE PROTEINS; BIOMARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MIDDLE AGED; POLYSACCHARIDES; RISK FACTORS; SMOKING;

EID: 84933074137     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305635     Document Type: Article

References (23)

1. Rabinovich GA, van Kooyk Y, Cobb BA. Glycobiology of immune responses. Ann N Y Acad Sci. 2012;1253:1-15. doi: 10.1111/j.1749-6632.2012.06492.x.
2. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126:855-867. doi: 10.1016/j.cell.2006.08.019.
3. Mariño K, Bones J, Kattla JJ, Rudd PM. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol. 2010;6:713-723. doi: 10.1038/nchembio.437.
4. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987;215:311-315.
5. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation [published online ahead of print March 16, 2015]. Clin Chem.
6. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep. 2013;13:435-444. doi: 10.1007/s11892-013-0375-y.
7. Badawi A, Klip A, Haddad P, Cole DE, Bailo BG, El-Sohemy A, Karmali M. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 2010;3:173-186.
8. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
9. Ohtsubo K, Chen MZ, Olefsky JM, Marth JD. Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport. Nat Med. 2011;17:1067-1075. doi: 10.1038/nm.2414.
10. Knezevic A, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, Rudd PM, Wright AF, Campbell H, Rudan I, Lauc G. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology. 2010;20:959-969. doi: 10.1093/glycob/cwq051.
11. Perry JR, Voight BF, Yengo L, et al; MAGIC; DIAGRAM Consortium; GIANT Consortium. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet. 2012;8:e1002741. doi: 10.1371/journal.pgen.1002741.
12. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-1652.
13. Higai K, Azuma Y, Aoki Y, Matsumoto K. Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin Chim Acta. 2003;329:117-125.
14. Sandström CS, Ohlsson B, Melander O, Westin U, Mahadeva R, Janciauskiene S. An association between type 2 diabetes and alpha-antitrypsin deficiency. Diabet Med. 2008;25:1370-1373. doi: 10.1111/j.1464-5491.2008.02584.x.
15. Hashemi M, Naderi M, Rashidi H, Ghavami S. Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract. 2007;75:246-248. doi: 10.1016/j.diabres.2006.06.020.
16. Fumeron F, Péan F, Driss F, Balkau B, Tichet J, Marre M, Grandchamp B; Insulin Resistance Syndrome (DESIR) Study Group. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care. 2006;29:2090-2094. doi: 10.2337/dc06-0093.
17. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, Shapiro S, Wright JL. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001;81:1119-1131.
18. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab. 2001;86:4398-4405. doi: 10.1210/jcem.86.9.7873.
19. O'Riordain MG, Ross JA, Fearon KC, Maingay J, Farouk M, Garden OJ, Carter DC. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol. 1995;269(2 pt 1):E323-E330.
20. Konrad RJ, Kudlow JE. The role of O-linked protein glycosylation in betacell dysfunction. Int J Mol Med. 2002;10:535-539.
21. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-1526. doi: 10.1056/NEJMoa065213.
22. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159:1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. doi: 10.1038/414813a.